Loading...
Delcath Q1 2025 Earnings Report
Delcath Systems reported its first quarter 2025 financial results and business highlights.
Key Takeaways
Delcath Systems achieved a strong start to 2025 with significant revenue growth, reaching $19.8 million, up from $3.1 million in the prior year. The company also reported its first quarter of net income of $1.1 million and positive operating cash flow, driven by the accelerating clinical adoption of HEPZATO.
Total revenue for Q1 2025 was $19.8 million, a substantial increase from $3.1 million in Q1 2024.
The company achieved a net income of $1.1 million in Q1 2025, a significant improvement from a net loss of $11.1 million in Q1 2024.
Cash and investments stood at $58.9 million as of March 31, 2025, with $2.2 million provided by operations during the quarter.
Delcath activated three new U.S. centers in Q1 2025 and two more in Q2 2025, bringing the total to 19 active centers, and received FDA clearance for a Phase 2 clinical trial of HEPZATO in liver-dominant metastatic breast cancer.
Delcath
Delcath
Delcath Revenue by Segment
Delcath Revenue by Geographic Location
Revenue by Segment
HEPZATO KIT Revenue
CapyFin.comCHEMOSAT Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comEurope Revenue
CapyFin.com Forward Guidance
Delcath Systems is focused on continued commercial expansion and clinical development of HEPZATO, aiming to broaden its indications and strengthen its market position.
Positive Outlook
- Continued commercial expansion activities, including marketing-related expenses and additional personnel in the commercial team, are expected to drive future growth.
- Initiation of the Phase 2 clinical trial evaluating HEPZATO in combination with standard of care for mCRC could open new market opportunities.
- Ongoing dialogue with oncologists and interventional radiologists reinforces the importance of whole-liver treatment, shaping future development strategy.
- The company's ability to obtain reimbursement for HEPZATO KIT is crucial for continued commercial success.
- Successful implementation and management of the HEPZATO KIT Risk Evaluation and Mitigation Strategy will support patient safety and market acceptance.
Challenges Ahead
- Uncertainties relating to the Company's commercialization plans and its ability to successfully commercialize HEPZATO KIT.
- Challenges in securing adequate supply of critical components necessary to manufacture and assemble HEPZATO KIT.
- Potential risks associated with successful FDA inspections of the facilities of the Company and those of its third-party suppliers/manufacturers.
- The company's ability to successfully enter into any necessary purchase and sale agreements with users of HEPZATO KIT.
- New risk factors and uncertainties may emerge over time, which are not currently predictable.
Revenue & Expenses
Visualization of income flow from segment revenue to net income